In this context, the 225Ac-PSMA-617 conjugate exhibited greater efficacy in patients with metastatic castration-resistant prostate cancer, even in cases resistant to 177Lu-PSMA-617 treatment 7. The gene discussed is FOLH1; the disease is Familial prostate cancer.